Insider Trading & Ownership of Robert E. Abernathy

Location
Boston, MA
Summary
The estimated net worth of Robert E. Abernathy is at least $3,140,642 dollars as of 02 Apr 2026. Robert E. Abernathy is the Director of HAEMONETICS CORP and owns shares of HAEMONETICS CORP (HAE) stock worth about $1.86M. Robert E. Abernathy is the Director of AVIENT CORP and owns shares of AVIENT CORP (AVNT) stock worth about $1.28M.
Signature
/s/ Robert K. James, Power of Attorney for Robert E. Abernathy
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Robert E. Abernathy and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Quick Takeaways

  • Robert E. Abernathy has 2 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $3,140,642.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: HAEMONETICS CORP ($1,863,832).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Robert E. Abernathy

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
HAE HAEMONETICS CORP Director $1,863,832 24 Jul 2025
AVNT AVIENT CORP Director $1,276,810 31 Mar 2026

Insider Transactions Reported by Robert E. Abernathy:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .